Home » Clinical Trials » Dementia
The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
Official Title: The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
The purpose of the study is to determine the long-term safety and exploratory efficacy of
NEUROSTEM®-AD, administered via an open brain surgery to subjects with dementia of the
Alzheimer's type, who were eligible for and enrolled in the earlier part of the phase I.
Aside from the subjects who completed the earlier part of the Phase I, 3 additional subjects
with comparable demographics and disease characteristics as the treatment group will be
enrolled into a control group, followed-up for 3 months, and compared for various disease
progression indicators with the treatment group.
The hypothesis is that NEUROSTEM®-AD is safe and effective in the treatment of dementia of
the Alzheimer's type.
Sponsor: Duk Lyul Na
Duk-Lyul Na, MD, PhD
|Korea, Republic of
||Samsung Medical Center
Duk L. Na, MD, PhD
Date Last Changed: September 27, 2012